Previous 10 | Next 10 |
BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the appointment of Nachum “Homi” Shamir to its ...
IsoPlexis Corporation (ISO) Q2 2022 Earnings Conference Call August 10, 2022 08:30 AM ET Company Participants Carrie Mendivil - IR Sean Mackay - CEO John Strahley - CFO Conference Call Participants Vijay Kumar - Evercore Max Masucci - Cowen Pu...
Gainers: Euro Tech Holdings ( CLWT ) +63% . Invitae ( NVTA ) +59% . Allego ( ALLG ) +54% . Grove Collaborative ( GROV ) +52% . BioAtla ( BCAB ) +40% . The Trade Desk ( TTD ) +37% . Chicken Soup for the Soul Entert...
IsoPlexis ( NASDAQ: ISO ) is trading ~33% lower after the company missed GAAP EPS estimates. The company posted quarterly loss of -$0.74, which missed estimates by $0.15. Operating costs rose 103% Y/Y to $30.7M, primarily driven by headcount ...
Gainers: OraSure Technologies ( OSUR ) +28% . BioAtla ( BCAB ) +24% . Catalyst Pharmaceuticals ( CPRX ) +16% . Clovis Oncology ( CLVS ) +13% . Quanterix ( QTRX ) +13% . Losers: Singular Genomics Systems ( OMIC ...
IsoPlexis press release ( NASDAQ: ISO ): Q2 GAAP EPS of -$0.65 misses by $0.10 . Revenue of $4M (-7.0% Y/Y) misses by $1.55M . Gross margin was 52% for the second quarter of 2022, as compared to 53% for the corresponding prior year period. IsoPlexis now exp...
BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 2022. Recent Highlights D...
BRANFORD, Conn., July 21, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the second quarter 2022 before market open on Wednesday, August 10, 2022. Company management will be webcasting a corresp...
IsoPlexis press release (NASDAQ:ISO): Q1 GAAP EPS of -$0.74 misses by $0.15. Revenue of $4.9M (+53.1% Y/Y) beats by $0.3M. 2022 Guidance: IsoPlexis continues to expect full year 2022 revenue to be in the range of $26 million to $27 million vs consensus of $26.31M, representing 51% to 56%...
BRANFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Revenue of $4.9 million for the first quarter 2022, representing a 52%...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) IsoEnergy Limited (TSX-V:ISO) president Tim Gabruch, delves into the strategic merger with Consolidated Uranium, marking a pivotal transformation into a global uranium industry contender. In an interview with Proactive's Angela Harmantas at PDAC 2024, Gabruch noted that t...
SASKATOON, Saskatchewan, Jan. 19, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an amended agreement with Eight Capital, as co-lead underwriter and joint bookrunner o...
SASKATOON, Saskatchewan, Jan. 18, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an agreement with Eight Capital to act as co-lead underwriter and joint bookrunner on ...